FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	'AL
OMB Number:	3235-0287
Estimated average bur	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Peen

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Millian Craig Stuart				2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						P]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 500 RIVER RIDGE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 02/02/2021							X_ Officer (give title below) Other (specify below) Chief Commercial Officer				
(Street) NORWOOD, MA 02062				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person lired, Disposed of, or Beneficially Owned				e)
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						es Acquire					
(Instr. 3) Da			2. Transaction Date (Month/Day/Year	Execution Date, if		Date, if C		8) (1	A) or Disposed onstr. 3, 4 and 5	Over (D) Over (In	Amount of So yned Followin nnsaction(s) str. 3 and 4)	ecurities Beneficially ing Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
Reminder:	Report on a s	separate line for each	class of securities b	peneficia	lly ov	wned direc	etly o	Person	s who respon	equired to	respond u				1474 (9-02)
			Table II					uired, Dispo	ntly valid OM sed of, or Beno nvertible secur	eficially Ov					
1. Title of Derivative Security (Instr. 3)		*****	3A. Deemed Execution Date, if	(e.g., p 4. Transac Code	tion		rants or of e (A) ed of	options, co 6. Date Exe Expiration I	sed of, or Benonvertible secur rcisable and Date	eficially Ov	d Amount ring		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Owners Form of Derivati Security Direct (or Indire	Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., p 4. Transac Code	tion	5. Number Derivative Securities Acquired or Dispose (D) (Instr. 3, 4	rants or of e (A) ed of	options, co 6. Date Exe Expiration I	sed of, or Bend nvertible secur reisable and Date //Year)	ricially Ovities) 7. Title an of Underly Securities	d Amount ring	Derivative Security	Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (or Indire	hip of Indire Benefici Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., p 4. Transac Code (Instr. 8	tion) V	5. Numbe Derivative Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	rants r of e (A) ed of 4,	uired, Dispo , options, co 6. Date Exe Expiration I (Month/Day	sed of, or Bend nvertible secur reisable and Date //Year)	ricially Ovities) 7. Title an of Underly Securities (Instr. 3 and	Amount or Number of Shares	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction	Owners Form of Derivati Security Direct (or Indirect) (I) (Instr. 4	hip of Indire Benefici Ownersh (Instr. 4)

Reporting Owners

P (0 N /	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Millian Craig Stuart 500 RIVER RIDGE DRIVE NORWOOD, MA 02062			Chief Commercial Officer			

Signatures

/s/ Sean Moran, attorney-in-fact for Craig Millian	02/04/2021
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022.
- (2) Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.